310 related articles for article (PubMed ID: 27237051)
21. Cystine Induced-mTORC2 Activation through Promoting Sin1 Phosphorylation to Suppress Cancer Cell Ferroptosis.
Wang G; Chen L; Qin S; Zheng Y; Xia C; Yao J; Wang P; Deng L
Mol Nutr Food Res; 2022 Dec; 66(23):e2200186. PubMed ID: 36189894
[TBL] [Abstract][Full Text] [Related]
22. PRR5, a novel component of mTOR complex 2, regulates platelet-derived growth factor receptor beta expression and signaling.
Woo SY; Kim DH; Jun CB; Kim YM; Haar EV; Lee SI; Hegg JW; Bandhakavi S; Griffin TJ; Kim DH
J Biol Chem; 2007 Aug; 282(35):25604-12. PubMed ID: 17599906
[TBL] [Abstract][Full Text] [Related]
23. AKT inhibition overcomes rapamycin resistance by enhancing the repressive function of PRAS40 on mTORC1/4E-BP1 axis.
Mi W; Ye Q; Liu S; She QB
Oncotarget; 2015 Jun; 6(16):13962-77. PubMed ID: 25961827
[TBL] [Abstract][Full Text] [Related]
24. Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility.
Gulati N; Karsy M; Albert L; Murali R; Jhanwar-Uniyal M
Int J Oncol; 2009 Oct; 35(4):731-40. PubMed ID: 19724909
[TBL] [Abstract][Full Text] [Related]
25. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells.
Jiang S; Zou Z; Nie P; Wen R; Xiao Y; Tang J
PLoS One; 2015; 10(7):e0132880. PubMed ID: 26176608
[TBL] [Abstract][Full Text] [Related]
26. SPH3643: A novel cyclin-dependent kinase 4/6 inhibitor with good anticancer efficacy and strong blood-brain barrier permeability.
Liao X; Hong Y; Mao Y; Chen N; Wang Q; Wang Z; Zhang L; Wang L; Shi C; Shi W; Ge H; Li A; Li X; Xia G; Liu Y
Cancer Sci; 2020 May; 111(5):1761-1773. PubMed ID: 32103527
[TBL] [Abstract][Full Text] [Related]
27. DNA-dependent protein kinase catalytic subunit (DNA-PKcs)-SIN1 association mediates ultraviolet B (UVB)-induced Akt Ser-473 phosphorylation and skin cell survival.
Tu Y; Ji C; Yang B; Yang Z; Gu H; Lu CC; Wang R; Su ZL; Chen B; Sun WL; Xia JP; Bi ZG; He L
Mol Cancer; 2013 Dec; 12(1):172. PubMed ID: 24365180
[TBL] [Abstract][Full Text] [Related]
28. Crosstalk between mTOR complexes.
Xie J; Proud CG
Nat Cell Biol; 2013 Nov; 15(11):1263-5. PubMed ID: 24189516
[TBL] [Abstract][Full Text] [Related]
29. CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest.
Wang J; Li Q; Yuan J; Wang J; Chen Z; Liu Z; Li Z; Lai Y; Gao J; Shen L
J Transl Med; 2017 Jun; 15(1):127. PubMed ID: 28578693
[TBL] [Abstract][Full Text] [Related]
30. mTORC2 is required for rit-mediated oxidative stress resistance.
Cai W; Andres DA
PLoS One; 2014; 9(12):e115602. PubMed ID: 25531880
[TBL] [Abstract][Full Text] [Related]
31. Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells.
Bonelli MA; Digiacomo G; Fumarola C; Alfieri R; Quaini F; Falco A; Madeddu D; La Monica S; Cretella D; Ravelli A; Ulivi P; Tebaldi M; Calistri D; Delmonte A; Ampollini L; Carbognani P; Tiseo M; Cavazzoni A; Petronini PG
Neoplasia; 2017 Aug; 19(8):637-648. PubMed ID: 28704762
[TBL] [Abstract][Full Text] [Related]
32. Phosphorylation of Akt at the C-terminal tail triggers Akt activation.
Liu P; Wang Z; Wei W
Cell Cycle; 2014; 13(14):2162-4. PubMed ID: 24933731
[TBL] [Abstract][Full Text] [Related]
33. Localization of mTORC2 activity inside cells.
Ebner M; Sinkovics B; Szczygieł M; Ribeiro DW; Yudushkin I
J Cell Biol; 2017 Feb; 216(2):343-353. PubMed ID: 28143890
[TBL] [Abstract][Full Text] [Related]
34. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
[TBL] [Abstract][Full Text] [Related]
35. Cell-cycle-regulated activation of Akt kinase by phosphorylation at its carboxyl terminus.
Liu P; Begley M; Michowski W; Inuzuka H; Ginzberg M; Gao D; Tsou P; Gan W; Papa A; Kim BM; Wan L; Singh A; Zhai B; Yuan M; Wang Z; Gygi SP; Lee TH; Lu KP; Toker A; Pandolfi PP; Asara JM; Kirschner MW; Sicinski P; Cantley L; Wei W
Nature; 2014 Apr; 508(7497):541-5. PubMed ID: 24670654
[TBL] [Abstract][Full Text] [Related]
36. Akt is efficiently activated by PIF-pocket- and PtdIns(3,4,5)P3-dependent mechanisms leading to resistance to PDK1 inhibitors.
Najafov A; Shpiro N; Alessi DR
Biochem J; 2012 Dec; 448(2):285-95. PubMed ID: 23030823
[TBL] [Abstract][Full Text] [Related]
37. Cyclin D-Cdk4,6 Drives Cell-Cycle Progression via the Retinoblastoma Protein's C-Terminal Helix.
Topacio BR; Zatulovskiy E; Cristea S; Xie S; Tambo CS; Rubin SM; Sage J; Kõivomägi M; Skotheim JM
Mol Cell; 2019 May; 74(4):758-770.e4. PubMed ID: 30982746
[TBL] [Abstract][Full Text] [Related]
38. The ATM inhibitor KU-55933 suppresses cell proliferation and induces apoptosis by blocking Akt in cancer cells with overactivated Akt.
Li Y; Yang DQ
Mol Cancer Ther; 2010 Jan; 9(1):113-25. PubMed ID: 20053781
[TBL] [Abstract][Full Text] [Related]
39. Ribociclib (LEE011) suppresses cell proliferation and induces apoptosis of MDA-MB-231 by inhibiting CDK4/6-cyclin D-Rb-E2F pathway.
Li T; Xiong Y; Wang Q; Chen F; Zeng Y; Yu X; Wang Y; Zhou F; Zhou Y
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):4001-4011. PubMed ID: 31588803
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells.
Chen BW; Chen W; Liang H; Liu H; Liang C; Zhi X; Hu LQ; Yu XZ; Wei T; Ma T; Xue F; Zheng L; Zhao B; Feng XH; Bai XL; Liang TB
Mol Cancer Ther; 2015 Aug; 14(8):1805-15. PubMed ID: 26026051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
